GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InNexus Biotechnology Inc (GREY:IXSBF) » Definitions » Net Income

IXSBF (InNexus Biotechnology) Net Income : $-4.15 Mil (TTM As of Mar. 2011)


View and export this data going back to . Start your Free Trial

What is InNexus Biotechnology Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. InNexus Biotechnology's Net Income for the three months ended in Mar. 2011 was $-0.57 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2011 was $-4.15 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. InNexus Biotechnology's Earnings per Share (Diluted) for the three months ended in Mar. 2011 was $-0.00.


InNexus Biotechnology Net Income Historical Data

The historical data trend for InNexus Biotechnology's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InNexus Biotechnology Net Income Chart

InNexus Biotechnology Annual Data
Trend Jun01 Jun02 Jun03 Jun04 Jun05 Jun06 Jun07 Jun08 Jun09 Jun10
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.63 -4.86 -5.79 -7.12 -6.45

InNexus Biotechnology Quarterly Data
Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.59 -1.84 -0.94 -0.79 -0.57

InNexus Biotechnology Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

InNexus Biotechnology's Net Income for the fiscal year that ended in Jun. 2010 is calculated as

Net Income(A: Jun. 2010 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0+0+0+-6.447
=-6.45

InNexus Biotechnology's Net Income for the quarter that ended in Mar. 2011 is calculated as

Net Income(Q: Mar. 2011 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=0+0+0+-0.569
=-0.57

Net Income for the trailing twelve months (TTM) ended in Mar. 2011 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InNexus Biotechnology  (GREY:IXSBF) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

InNexus Biotechnology's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2011 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


InNexus Biotechnology Net Income Related Terms

Thank you for viewing the detailed overview of InNexus Biotechnology's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


InNexus Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
1055 West Georgia Street, 1500 Royal Centre, Vancouver, BC, CAN, V6E 4N7
InNexus Biotechnology Inc is engaged in commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications.

InNexus Biotechnology Headlines

No Headlines